Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Tóm tắt
Pancreatic ductal adenocarcinoma (PDAC) is considered a “nonimmunogenic” neoplasm. Single-agent immunotherapies have failed to demonstrate significant clinical activity in PDAC and other “nonimmunogenic” tumors, in part due to a complex tumor microenvironment (TME) that provides a formidable barrier to immune infiltration and function. We designed a neoadjuvant and adjuvant clinical trial comparing an irradiated, granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting, allogeneic PDAC vaccine (GVAX) given as a single agent or in combination with low-dose cyclophosphamide to deplete regulatory T cells (Treg) as a means to study how the TME is altered by immunotherapy. Examination of resected PDACs revealed the formation of vaccine-induced intratumoral tertiary lymphoid aggregates in 33 of 39 patients 2 weeks after vaccine treatment. Immunohistochemical analysis showed these aggregates to be regulatory structures of adaptive immunity. Microarray analysis of microdissected aggregates identified gene-expression signatures in five signaling pathways involved in regulating immune-cell activation and trafficking that were associated with improved postvaccination responses. A suppressed Treg pathway and an enhanced Th17 pathway within these aggregates were associated with improved survival, enhanced postvaccination mesothelin-specific T-cell responses, and increased intratumoral Teff:Treg ratios. This study provides the first example of immune-based therapy converting a “nonimmunogenic” neoplasm into an “immunogenic” neoplasm by inducing infiltration of T cells and development of tertiary lymphoid structures in the TME. Post-GVAX T-cell infiltration and aggregate formation resulted in the upregulation of immunosuppressive regulatory mechanisms, including the PD-1–PD-L1 pathway, suggesting that patients with vaccine-primed PDAC may be better candidates than vaccine-naïve patients for immune checkpoint and other immunomodulatory therapies. Cancer Immunol Res; 2(7); 616–31. ©2014 AACR.
Từ khóa
Tài liệu tham khảo
American Cancer Society, 2012, Cancer facts and figures
Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609
Hodi, 2008, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Proc Natl Acad Sci U S A, 105, 3005, 10.1073/pnas.0712237105
Sharma, 2011, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nat Rev Cancer, 11, 805, 10.1038/nrc3153
Clark, 2009, Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer, Cancer Lett, 279, 1, 10.1016/j.canlet.2008.09.037
Hiraoka, 2006, Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions, Clin Cancer Res, 12, 5423, 10.1158/1078-0432.CCR-06-0369
von Bernstorff, 2001, Systemic and local immunosuppression in pancreatic cancer patients, Clin Cancer Res, 7, 925s
Koido, 2011, Current immunotherapeutic approaches in pancreatic cancer, Clin Dev Immunol, 2011, 267539, 10.1155/2011/267539
Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694
Royal, 2010, Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J Immunother, 33, 828, 10.1097/CJI.0b013e3181eec14c
Le, 2013, Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer, J Immunother, 36, 382, 10.1097/CJI.0b013e31829fb7a2
Jaffee, 2001, Novel allogeneic granulocyte-macrophage colony-stimulating factor–secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation, J Clin Oncol, 19, 145, 10.1200/JCO.2001.19.1.145
Jaffee, 1998, Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials, Cancer J Sci Am, 4, 194
Laheru, 2008, Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation, Clin Cancer Res, 14, 1455, 10.1158/1078-0432.CCR-07-0371
Lutz, 2011, A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation, Ann Surg, 253, 328, 10.1097/SLA.0b013e3181fd271c
Thomas, 2004, Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients, J Exp Med, 200, 297, 10.1084/jem.20031435
Gajewski, 2006, Immune resistance orchestrated by the tumor microenvironment, Immunol Rev, 213, 131, 10.1111/j.1600-065X.2006.00442.x
Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, 10, 942, 10.1038/nm1093
Liyanage, 2002, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, J Immunol, 169, 2756, 10.4049/jimmunol.169.5.2756
Mougiakakos, 2010, Regulatory T cells in cancer, Adv Cancer Res, 107, 57, 10.1016/S0065-230X(10)07003-X
Ercolini, 2005, Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response, J Exp Med, 201, 1591, 10.1084/jem.20042167
Ghiringhelli, 2004, CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative, Eur J Immunol, 34, 336, 10.1002/eji.200324181
Hermans, 2003, Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model, Cancer Res, 63, 8408
Leao, 2008, Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma, Clin Transl Sci, 1, 228, 10.1111/j.1752-8062.2008.00070.x
Weiss, 2012, Targeting the right regulatory T-cell population for tumor immunotherapy, Oncoimmunology, 1, 1191, 10.4161/onci.20664
Weiss, 2012, Trafficking of high avidity HER-2/neu–specific T cells into HER-2/neu–expressing tumors after depletion of effector/memory-like regulatory T cells, PLoS ONE, 7, e31962, 10.1371/journal.pone.0031962
Cipponi, 2012, Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases, Cancer Res, 72, 3997, 10.1158/0008-5472.CAN-12-1377
Messina, 2012, 12-Chemokine gene signature identifies lymph node–like structures in melanoma: potential for patient selection for immunotherapy?, Sci Rep, 2, 765, 10.1038/srep00765
Coppola, 2011, Unique ectopic lymph node–like structures present in human primary colorectal carcinoma are identified by immune gene array profiling, Am J Pathol, 179, 37, 10.1016/j.ajpath.2011.03.007
Dieu-Nosjean, 2008, Long-term survival for patients with non–small-cell lung cancer with intratumoral lymphoid structures, J Clin Oncol, 26, 4410, 10.1200/JCO.2007.15.0284
Spranger, 2013, Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells, Sci Transl Med, 5, 200ra116, 10.1126/scitranslmed.3006504
Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689
Ghiringhelli, 2007, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol immunother, 56, 641, 10.1007/s00262-006-0225-8
Bigelow, 2013, Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue, J Vis Exp, 4059
Lubbers, 2013, The type I IFN signature as a biomarker of preclinical rheumatoid arthritis, Ann Rheum Dis, 72, 776, 10.1136/annrheumdis-2012-202753
Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, 102, 15545, 10.1073/pnas.0506580102
van Nierop, 2002, Human follicular dendritic cells: function, origin and development, Sem Immunol, 14, 251, 10.1016/S1044-5323(02)00057-X
Fan, 2000, Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis, J Immunol, 164, 3955, 10.4049/jimmunol.164.8.3955
Kline, 2010, Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer, Curr Opin Investig Drugs, 11, 1354
Ino, 2013, Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer, Br J Cancer, 108, 914, 10.1038/bjc.2013.32
Shen, 2010, Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer, J Cancer Res Clin Oncol, 136, 1585, 10.1007/s00432-010-0816-9
Sinicrope, 2009, Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma, Gastroenterology, 137, 1270, 10.1053/j.gastro.2009.06.053
Chauhan, 2014, CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue, J Immunol, 192, 817, 10.4049/jimmunol.1203469
Chen, 2013, High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma, Oncol Rep, 30, 1380, 10.3892/or.2013.2603
Chenivesse, 2012, Pulmonary CCL18 recruits human regulatory T cells, J Immunol, 189, 128, 10.4049/jimmunol.1003616
Porta, 2007, Tumor promotion by tumor-associated macrophages, Adv Exp Med Biol, 604, 67, 10.1007/978-0-387-69116-9_5
Sawanobori, 2008, Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice, Blood, 111, 5457, 10.1182/blood-2008-01-136895
Haile, 2010, CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice, J Immunol, 185, 203, 10.4049/jimmunol.0903573
Jin, 2009, Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK, Blood, 113, 6603, 10.1182/blood-2008-12-192914
Ruan, 2012, Nuclear factor-kappaB in immunity and inflammation: the Treg and Th17 connection, Adv Exp Med Biol, 946, 207, 10.1007/978-1-4614-0106-3_12
Chang, 2012, Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells, Nat Immunol, 13, 481, 10.1038/ni.2267
Ciofani, 2012, A validated regulatory network for Th17 cell specification, Cell, 151, 289, 10.1016/j.cell.2012.09.016
Lee, 2009, Late developmental plasticity in the T helper 17 lineage, Immunity, 30, 92, 10.1016/j.immuni.2008.11.005
Aloisi, 2006, Lymphoid neogenesis in chronic inflammatory diseases, Nat Rev Immunol, 6, 205, 10.1038/nri1786
Hjelmstrom, 2001, Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines, J Leuk Biol, 69, 331, 10.1189/jlb.69.3.331
Quezada, 2006, CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells, J Clin Invest, 116, 1935, 10.1172/JCI27745
Weih, 2003, Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway, Immunol Rev, 195, 91, 10.1034/j.1600-065X.2003.00064.x
Foo, 2010, Regulation of inducible BALT formation and contribution to immunity and pathology, Mucosal immunol, 3, 537, 10.1038/mi.2010.52
Kocks, 2007, Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue, J Exp Med, 204, 723, 10.1084/jem.20061424
Grogan, 2012, A role for Th17 cells in the regulation of tertiary lymphoid follicles, Eur J Immunol, 42, 2255, 10.1002/eji.201242656
Peters, 2011, Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation, Immunity, 35, 986, 10.1016/j.immuni.2011.10.015
Wang, 2009, IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway, J Exp Med, 206, 1457, 10.1084/jem.20090207
Acosta-Rodriguez, 2007, Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17–producing human T helper cells, Nat Immunol, 8, 942, 10.1038/ni1496
Hirota, 2011, Fate mapping of IL-17–producing T cells in inflammatory responses, Nat Immunol, 12, 255, 10.1038/ni.1993
Muranski, 2013, Essentials of Th17 cell commitment and plasticity, Blood, 121, 2402, 10.1182/blood-2012-09-378653
Zielinski, 2012, Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta, Nature, 484, 514, 10.1038/nature10957
Martin, 2012, Controversies on the role of Th17 in cancer: a TGF-beta–dependent immunosuppressive activity?, Trends in Mol Med, 18, 742, 10.1016/j.molmed.2012.09.007
Wilke, 2011, Th17 cells in cancer: help or hindrance?, Carcinogenesis, 32, 643, 10.1093/carcin/bgr019